ReviewJournal of nanobiotechnology2026
Nanotechnology for reproductive healthcare: a comprehensive review.
Review in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanotechnology in reproductive medicine: from gamete engineering to precision therapeutics.RSC advances · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The advancement of nanotechnology has revolutionized reproductive healthcare worldwide. It has enabled the treatment of various conditions, such as infertility, endometriosis, ectopic pregnancies, erectile dysfunction, sexually transmitted infections (STIs), and reproductive tissue cancers. Nanotechnology offers improved imaging, personalized drug administration, and early diagnosis, leading to more accurate treatment outcomes. It can enhance fertility preservation, improve individualized therapy, and improve diagnostic methods. Additionally, nanotechnology-powered drug delivery systems increase effectiveness while reducing side effects. Clinical trials utilizing nanoparticles for cellular treatments, targeted drug delivery, early infection detection, reproductive system malignancies and precise medication delivery are currently underway. Nanotechnology has opened new possibilities in areas such as disease detection, drug administration, diagnostic imaging, and cancer treatment. This review aims to provide an overview of the different types, characteristics, and synthesis methods of nanocarriers designed for medication delivery in the context of reproductive disorders and diseases. It seeks to enhance the understanding of the current state of the art and explore potential future advancements in this field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.